Literature DB >> 35083119

Underlying Coronary Microvascular Disease May Lead to Underestimation of Global Longitudinal Strain Differences.

Neelesh Gupta1, Mohammed Elkhazendar2, Rajeev Gupta3.   

Abstract

Entities:  

Year:  2021        PMID: 35083119      PMCID: PMC8754449          DOI: 10.37616/2212-5043.1272

Source DB:  PubMed          Journal:  J Saudi Heart Assoc        ISSN: 1016-7315


× No keyword cloud information.
To the Editor: We read with interest the original article by Srinivasan G, et al. [1]. In the study, the methodology stated that “Participants with normal coronaries and non-obstructive disease were taken as the control group.” The speckle-tracking Echocardiography-derived Global Longitudinal Strain (GLS) is a sensitive modality for obtaining the GLS. The participants presenting with chest pain with normal coronaries on angiography and non-obstructive disease accepted as control may have microvascular coronary artery disease affecting the control GLS values, leading to underestimation of the difference between the disease and control group. Studies have shown that patients with coronary microvascular disease are known to have a significant lowering of coronary reserves, thus affecting patterns of GLS [2,3]. Thereby, this should be taken into consideration when interpreting the results of this study.
  2 in total

1.  Independence of coronary artery disease to subclinical left ventricular dysfunction.

Authors:  Prasanna Venkataraman; Leah Wright; Quan Huynh; Thomas H Marwick
Journal:  Echocardiography       Date:  2020-04-21       Impact factor: 1.724

2.  Impairment of coronary flow velocity reserve and global longitudinal strain in women with cardiac syndrome X and slow coronary flow.

Authors:  Ivana Jovanovic; Milorad Tesic; Vojislav Giga; Milan Dobric; Nikola Boskovic; Jelena Vratonjic; Dejan Orlic; Ognjen Gudelj; Miloje Tomasevic; Miodrag Dikic; Ivana Nedeljkovic; Danijela Trifunovic; Milan A Nedeljkovic; Srdjan Dedic; Branko Beleslin; Ana Djordjevic-Dikic
Journal:  J Cardiol       Date:  2020-05-06       Impact factor: 3.159

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.